Record Information
Version1.0
Creation Date2009-07-21 20:27:20 UTC
Update Date2026-04-05 12:25:14 UTC
Accession NumberCHEM002238
Identification
Common NamePteroyl-D-glutamic acid
ClassSmall Molecule
DescriptionThe active metabolite of Folic acid, Pteroyl-D-glutamic acid is used principally as its calcium salt as an antidote to folic acid antagonists which block the conversion of folic acid to folinic acid. Folic acid, a water-soluble B-complex vitamin, is found in foods such as liver, kidneys, yeast, and leafy, green vegetables. Folic acid is used to diagnose folate deficiency and to treat topical sprue and megaloblastic and macrocytic anemias, hematologic complications resulting from a deficiency in folic acid. A member of the vitamin B family that stimulates the hematopoietic system. It is present in the liver and kidney and is found in mushrooms, spinach, yeast, green leaves, and grasses (poaceae). Folic acid is used in the treatment and prevention of folate deficiencies and megaloblastic anemia.
Contaminant Sources
  • FooDB Chemicals
  • STOFF IDENT Compounds
  • T3DB toxins
Contaminant Type
  • Amide
  • Amine
  • Anti-Anemic Agent
  • Antidote
  • Antineoplastic, Adjunct
  • Drug
  • Ester
  • Food Toxin
  • Metabolite
  • Natural Compound
  • Organic Compound
  • Plant Toxin
  • Vitamin
  • Vitamin B Complex
Chemical Structure
Thumb
Synonyms
ValueSource
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acidChEBI
(6S)-Folinic acidChEBI
(6S)-LeucovorinChEBI
(S)-LeucovorinChEBI
Citrovorum factorChEBI
L-Folinic acidChEBI
LevofoleneChEBI
Levofolinic acidChEBI
LevoleucovorinChEBI
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acidChEBI
(6S)-5-Formyl-5,6,7,8-tetrahydrofolateGenerator
(6S)-FolinateGenerator
L-FolinateGenerator
LevofolinateGenerator
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamateGenerator
FolinateGenerator
5-FormyltetrahydrofolateHMDB
Pteroyl-D-glutamateHMDB
5 FormyltetrahydropteroylglutamateHMDB
5-FormyltetrahydropteroylglutamateHMDB
Calcium folinateHMDB
Folinic acid-SFHMDB
LeucovorinHMDB
Leucovorin, (S)-isomerHMDB
Leucovorin, monosodium saltHMDB
Leucovorin, (R)-isomerHMDB
Leucovorin, calciumHMDB
Leucovorin, calcium (1:1) salt, (DL)-isomerHMDB
Leucovorin, calcium (1:1) salt, (S)-isomerHMDB
LeukovorinHMDB
LeukovorumHMDB
Monosodium salt leucovorinHMDB
WellcovorinHMDB
Levo leucovorinHMDB
6 S LeucovorinHMDB
Acid, folinicHMDB
Factor, citrovorumHMDB
Folinic acid SFHMDB
FusilevHMDB
Leucovorin, calcium (1:1) salt, pentahydrateHMDB
Leucovorin, monopotassium salt, (S)-isomerHMDB
N(5)-FormyltetrahydrofolateHMDB
S-LeucovorinHMDB
5 FormyltetrahydrofolateHMDB
6-S-LeucovorinHMDB
6S LeucovorinHMDB
6S-LeucovorinHMDB
Calcium leucovorinHMDB
Folinate, calciumHMDB
Leucovorin, (D)-isomerHMDB
Leucovorin, (DL)-isomerHMDB
Leucovorin, calcium (1:1) saltHMDB
Leucovorin, monosodium salt, (S)-isomerHMDB
S LeucovorinHMDB
Levo-leucovorinHMDB
5-Formyl-(6S)-tetrahydrofolic acidHMDB
5-Formyl-5,6,7,8-tetrahydrofolic acidHMDB
5-Formyltetrahydrofolic acidHMDB
5-Formyltetrahydropteroylglutamic acidHMDB
CFHMDB
KunyrinHMDB
LeucoverinHMDB
N5-Formyl-5,6,7,8-tetrahydrofolic acidHMDB
N5-Formyl-THFHMDB
N5-Formyltetrahydrofolic acidHMDB
WelcovorinHMDB
(6S)-5-FormyltetrahydrofolateHMDB
(6S)-5-Formyltetrahydrofolic acidHMDB
Folinic acidMeSH
Chemical FormulaC20H23N7O7
Average Molecular Mass473.439 g/mol
Monoisotopic Mass473.166 g/mol
CAS Registry Number1492-18-8
IUPAC Name(2S)-2-{[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]formamido}pentanedioic acid
Traditional Name(2S)-2-{[4-({[(6S)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methyl}amino)phenyl]formamido}pentanedioic acid
SMILESNC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1
InChI IdentifierInChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12-,13-/m0/s1
InChI KeyVVIAGPKUTFNRDU-STQMWFEESA-N
Chemical Taxonomy
Description belongs to the class of organic compounds known as tetrahydrofolic acids. These are heterocyclic compounds based on the 5,6,7,8-tetrahydropteroic acid skeleton conjugated with at least one L-glutamic acid unit.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPteridines and derivatives
Sub ClassPterins and derivatives
Direct ParentTetrahydrofolic acids
Alternative Parents
Substituents
  • Tetrahydrofolic acid
  • Glutamic acid or derivatives
  • N-acyl-alpha amino acid or derivatives
  • N-acyl-alpha-amino acid
  • Hippuric acid
  • Hippuric acid or derivatives
  • Alpha-amino acid or derivatives
  • Aminobenzamide
  • Aminobenzoic acid or derivatives
  • Benzamide
  • Benzoic acid or derivatives
  • Benzoyl
  • Aniline or substituted anilines
  • Phenylalkylamine
  • Aminopyrimidine
  • Secondary aliphatic/aromatic amine
  • Pyrimidone
  • Dicarboxylic acid or derivatives
  • Benzenoid
  • Pyrimidine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Vinylogous amide
  • Tertiary carboxylic acid amide
  • Secondary carboxylic acid amide
  • Amino acid or derivatives
  • Amino acid
  • Carboxamide group
  • Secondary amine
  • Carboxylic acid
  • Carboxylic acid derivative
  • Azacycle
  • Organooxygen compound
  • Carbonyl group
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Amine
  • Organic oxide
  • Organopnictogen compound
  • Organic oxygen compound
  • Primary amine
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Biological Properties
StatusDetected and Not Quantified
OriginEndogenous
Cellular Locations
  • Membrane
Biofluid LocationsNot Available
Tissue LocationsNot Available
PathwaysNot Available
ApplicationsNot Available
Biological RolesNot Available
Chemical RolesNot Available
Physical Properties
StateSolid
AppearanceWhite powder.
Experimental Properties
PropertyValue
Melting Point245°C
Boiling PointNot Available
SolubilityComplete
Predicted Properties
PropertyValueSource
Water Solubility0.3 g/LALOGPS
logP-1.1ALOGPS
logP-2.7ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)3.47ChemAxon
pKa (Strongest Basic)2.81ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area215.55 ŲChemAxon
Rotatable Bond Count9ChemAxon
Refractivity126.46 m³·mol⁻¹ChemAxon
Polarizability46.34 ųChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Spectra
Spectra
Spectrum TypeDescriptionSplash KeyView
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, PositiveNot AvailableSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-0adi-0031900000-15cbae867ecd4a003ef0Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0a6r-0393400000-73f11f6c59198eafb45fSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0pb9-0591000000-ea5c6303d77ffa4af0cbSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-00di-0000900000-a3ae54a4d9b2cae45b72Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-00bc-1243900000-4ea7b3b1902e6a1204e5Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0007-7973000000-df3edd5bd8661611dd06Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-00fr-0005900000-5985bdc6c069ecc00046Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-056s-1597400000-db859aadd61942f2e80bSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-05o0-0921000000-ddf359b6fc3776d45401Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-004i-0000900000-56bf354a786254d088f4Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-0fb9-1220900000-d93259006e38248d26b4Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0f6x-5920100000-575460bfef119781af80Spectrum
1D NMR1H NMR SpectrumNot AvailableSpectrum
1D NMR13C NMR SpectrumNot AvailableSpectrum
1D NMR1H NMR SpectrumNot AvailableSpectrum
1D NMR13C NMR SpectrumNot AvailableSpectrum
1D NMR1H NMR SpectrumNot AvailableSpectrum
1D NMR13C NMR SpectrumNot AvailableSpectrum
1D NMR1H NMR SpectrumNot AvailableSpectrum
1D NMR13C NMR SpectrumNot AvailableSpectrum
1D NMR1H NMR SpectrumNot AvailableSpectrum
1D NMR13C NMR SpectrumNot AvailableSpectrum
1D NMR1H NMR SpectrumNot AvailableSpectrum
1D NMR13C NMR SpectrumNot AvailableSpectrum
1D NMR1H NMR SpectrumNot AvailableSpectrum
1D NMR13C NMR SpectrumNot AvailableSpectrum
1D NMR1H NMR SpectrumNot AvailableSpectrum
1D NMR13C NMR SpectrumNot AvailableSpectrum
1D NMR1H NMR SpectrumNot AvailableSpectrum
1D NMR13C NMR SpectrumNot AvailableSpectrum
1D NMR1H NMR SpectrumNot AvailableSpectrum
1D NMR13C NMR SpectrumNot AvailableSpectrum
Toxicity Profile
Route of ExposureFollowing oral administration, leucovorin is rapidly absorbed. The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
Mechanism of ToxicityAs leucovorin is a derivative of folic acid, it can be used to increase levels of folic acid under conditions favoring folic acid inhibition (following treatment of folic acid antagonists such as methotrexate). Leucovorin enhances the activity of fluorouracil by stabilizing the bond of the active metabolite (5-FdUMP) to the enzyme thymidylate synthetase.
MetabolismHepatic and intestinal mucosal, the main metabolite being the active 5-methyltetrahydrofolate. Leucovorin is readily converted to another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of fluorodeoxyridylic acid to thymidylate synthase and thereby enhances the inhibition of this enzyme. Half Life: 6.2 hours
Toxicity ValuesLD50: >8000 mg/kg (oral, rats).
Lethal DoseNot Available
Carcinogenicity (IARC Classification)No indication of carcinogenicity to humans (not listed by IARC).
Uses/SourcesFor the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Used in cancer chemotherapy involving the drug methotrexate.
Minimum Risk LevelNot Available
Health EffectsShould not be administered intrathecally as this may produce severe adverse effects or even death when administered. [Wikipedia]. Allergic sensitization (<1%), including anaphylactoid reactions
SymptomsExcessive amounts of leucovorin may nullify the chemotherapeutic effect of folic acid antagonists.
TreatmentNot Available
Concentrations
Not Available
DrugBank IDDB11596
HMDB IDHMDB0001562
FooDB IDFDB112383
Phenol Explorer IDNot Available
KNApSAcK IDC00050578
BiGG IDNot Available
BioCyc IDNot Available
METLIN IDNot Available
PDB IDNot Available
Wikipedia LinkFolinic acid
Chemspider ID131714
ChEBI ID63606
PubChem Compound ID149436
Kegg Compound IDC03479
YMDB IDYMDB00516
ECMDB IDNot Available
References
Synthesis Reference

James C. Wisowaty, Roy A. Swaringen, David A. Yeowell, “Synthesis of leucovorin.” U.S. Patent US4500711, issued July, 1955.

MSDSLink
General References
1. https://www.ncbi.nlm.nih.gov/pubmed/?term=11135086
2. https://www.ncbi.nlm.nih.gov/pubmed/?term=11748463
3. https://www.ncbi.nlm.nih.gov/pubmed/?term=12427152
4. https://www.ncbi.nlm.nih.gov/pubmed/?term=18343754
5. https://www.ncbi.nlm.nih.gov/pubmed/?term=18593999
6. https://www.ncbi.nlm.nih.gov/pubmed/?term=19712610
7. https://www.ncbi.nlm.nih.gov/pubmed/?term=20204366
8. https://www.ncbi.nlm.nih.gov/pubmed/?term=20399639
9. https://www.ncbi.nlm.nih.gov/pubmed/?term=21239357
10. https://www.ncbi.nlm.nih.gov/pubmed/?term=21907007
11. https://www.ncbi.nlm.nih.gov/pubmed/?term=22055112
12. https://www.ncbi.nlm.nih.gov/pubmed/?term=7777248
13. https://www.ncbi.nlm.nih.gov/pubmed/?term=8404828
14. Zakrzewski, Sigmund F.; Sansone, Annette M. Preparation of folinic acid (N5-formyltetrahydro folic acid). Methods Enzymol. (1971), 18(Pt. B), 731-3.
15. Micke O, Bruns F, Schafer U, Kurowski R, Horst E, Willich N: CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res. 2003 Mar-Apr;23(2A):835-40.
16. Garbis SD, Melse-Boonstra A, West CE, van Breemen RB: Determination of folates in human plasma using hydrophilic interaction chromatography-tandem mass spectrometry. Anal Chem. 2001 Nov 15;73(22):5358-64.
17. Pfeiffer CM, Fazili Z, McCoy L, Zhang M, Gunter EW: Determination of folate vitamers in human serum by stable-isotope-dilution tandem mass spectrometry and comparison with radioassay and microbiologic assay. Clin Chem. 2004 Feb;50(2):423-32. Epub 2003 Dec 11.
18. Karakayali FY, Bayar S, Hazinedaroglu S, Sahin F, Karayalcin K: Does folinic acid have a choleretic effect on humans? Turk J Gastroenterol. 2003 Jun;14(2):102-5.
19. Perry TL, Applegarth DA, Evans ME, Hansen S, Jellum E: Metabolic studies of a family with massive formiminoglutamic aciduria. Pediatr Res. 1975 Mar;9(3):117-22.
20. Pineda M, Ormazabal A, Lopez-Gallardo E, Nascimento A, Solano A, Herrero MD, Vilaseca MA, Briones P, Ibanez L, Montoya J, Artuch R: Cerebral folate deficiency and leukoencephalopathy caused by a mitochondrial DNA deletion. Ann Neurol. 2006 Feb;59(2):394-8.
21. Birmingham BK, Greene DS: Analysis of folinic acid in human serum using high-performance liquid chromatography with amperometric detection. J Pharm Sci. 1983 Nov;72(11):1306-9.
22. Sengelov L, von der Maase H, Lundbeck F, Barlebo H, Colstrup H, Engelholm SA, Krarup T, Madsen EL, Meyhoff HH, Mommsen S, Nielsen OS, Pedersen D, Steven K, Sorensen B: Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol. 2002;41(5):447-56.
23. Bunni MA, Priest DG: Human red blood cell-mediated metabolism of leucovorin [(R,S)5-formyltetrahydrofolate]. Arch Biochem Biophys. 1991 May 1;286(2):633-7.
24. Ramaekers VT, Hausler M, Opladen T, Heimann G, Blau N: Psychomotor retardation, spastic paraplegia, cerebellar ataxia and dyskinesia associated with low 5-methyltetrahydrofolate in cerebrospinal fluid: a novel neurometabolic condition responding to folinic acid substitution. Neuropediatrics. 2002 Dec;33(6):301-8.
25. Zhu WY, Alliegro MA, Melera PW: The rate of folate receptor alpha (FR alpha) synthesis in folate depleted CHL cells is regulated by a translational mechanism sensitive to media folate levels, while stable overexpression of its mRNA is mediated by gene amplification and an increase in transcript half-life. J Cell Biochem. 2001 Mar 26;81(2):205-19.
26. Jansman FG, Coenen JL, De Graaf JC, Tobi H, Sleijfer DT, Brouwers JR: Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid. Anticancer Res. 2002 Nov-Dec;22(6B):3449-55.
27. Vimercati A, Greco P, D'Apolito A, Angelici MC, Possenti A, Carbonara S, Selvaggi L: [Risk assessment of vertical transmission of Toxoplasma infections]. Acta Biomed Ateneo Parmense. 2000;71 Suppl 1:537-40.
28. Joulia JM, Pinguet F, Ychou M, Duffour J, Astre C, Bressolle F: Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. Eur J Cancer. 1999 Feb;35(2):296-301.
29. Polyzos A, Kouraklis G, Giannopoulos A, Bramis J, Delladetsima JK, Sfikakis PP: Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients. J Chemother. 2003 Oct;15(5):503-6.
30. Straw JA, Szapary D, Wynn WT: Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res. 1984 Jul;44(7):3114-9.
31. Micke O, Hesselmann S, Bruns F, Horst E, Devries A, Schuller P, Willich N, Schafer U: Results and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res. 2005 May-Jun;25(3A):1523-30.
32. Bentivoglio G, Melica F, Cristoforoni P: Folinic acid in the treatment of human male infertility. Fertil Steril. 1993 Oct;60(4):698-701.
33. Kajiyama Y, Tsurumaru M, Udagawa H, Tsutsumi K, Kinoshita Y, Akiyama H: Relief of jaundice by 5-fluorouracil and folinic acid in patients with recurrent gastric cancer. Surg Oncol. 1996 Aug;5(4):177-81.
34. Jardine LF, Ingram LC, Bleyer WA: Intrathecal leucovorin after intrathecal methotrexate overdose. J Pediatr Hematol Oncol. 1996 Aug;18(3):302-4.